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Abstract
Background: Rheumatoid arthritis synovial fibroblasts (RASFs) are known to travel via the bloodstream from sites of
cartilage destruction to new locations where they reinitiate the destructive processes at distant articular cartilage
surfaces. In this study, we examined the role of interleukin (IL)-1-induced cartilage changes and their chemotactic
effect on RASF transmigratory capacity.
Methods: To investigate synovial fibroblast (SF) transmigration through endothelial layers, we used a modified
Boyden chamber with an endothelioma cell layer (bEnd.5) as a barrier and IL-1-treated murine cartilage explants
as a chemotactic stimulus for SFs from human tumor necrosis factor–transgenic (hTNFtg) mice. We injected
recombinant IL-1 or collagenase into knee joints of wild-type mice, followed by tail vein injection of
fluorescence-labeled hTNFtg SFs. The distribution and intensity of transmigrating hTNFtg SFs were measured by
fluorescence reflectance imaging with X-ray coregistration. Toluidine blue staining was performed to evaluate
the amount of cartilage destruction.
Results: Histomorphometric analyses and in vivo imaging revealed a high degree of cartilage proteoglycan loss
after intra-articular IL-1 and collagenase injection, accompanied by an enhanced in vivo extravasation of hTNFtg
SFs into the respective knee joints, suggesting that structural cartilage damage contributes significantly to the
attraction of hTNFtg SFs into these joints. In vitro results showed that degraded cartilage was directly responsible
for the enhanced transmigratory capacity because stimulation with IL-1-treated cartilage, but not with IL-1 or
cartilage alone, was required to increase hTNFtg SF migration.
Conclusions: The present data indicate that structural cartilage damage facilitates the migration of arthritic SF
into affected joints. The prevention of early inflammatory cartilage damage may therefore help prevent the
progression of rheumatoid arthritis and its spread to previously unaffected joints.
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory
disorder that leads to symmetrical polyarthritis charac-
terized by synovial inflammation, cartilage destruction,
and bone erosions [1, 2]. Research in recent years has
identified synovial fibroblasts (SFs) in the lining layer of
the hyperplastic synovial membrane as key player in the
destructive process in RA [3]. SFs actively contribute to
joint destruction by their secretion of matrix-degrading
enzymes and inflammatory cytokines [3–6]. This aggres-
sive phenotype is unique for SFs obtained from patients
with RA (RASFs) [7]. Interestingly, RASFs retain their
destructive potential in the absence of an inflammatory
environment, as demonstrated by studies using mice
with severe combined immunodeficiency (SCID) [8, 9].
In a recently published study using this SCID mouse
model, it was shown that RASFs are more than just
resident, immobile cells within the destructive synovial
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pannus. They have been suggested to contribute to the
spreading of disease by their ability to leave cartilage
destruction sites, migrate via the bloodstream, and
reinitiate the destructive process at distant articular
cartilage surfaces [10].
Because the ability of RASFs to enter and leave the
bloodstream was demonstrated in a SCID mouse coim-
plantation model, it must be at least in part independent
on a stimulated immune system. This suggests that not
only cytokines implicated in immune processes but also
other signals attract RASFs to cartilage surfaces and
facilitate their transmigration at sites of extravasation. In
this context, structural changes occurring in the articular
cartilage early in the course of RA might be of import-
ance as such signal for the diapedesis of RASFs. At
present, very little is known about the early patho-
logical changes within articular cartilage during RA,
although it is widely agreed that biocellular changes
precede the onset of arthritis development [11, 12].
Also, several lines of evidence suggest that cartilage
damage, and particularly the loss of proteoglycans, pre-
cedes the attachment and activation of SFs at least in
animal models of RA [13, 14].
On the basis of these data, we hypothesized that, in
addition to alterations in the immune response, early
cartilage damage is one important factor contributing to
joints being affected by RA and potentially in the spread
of the disease by attracting activated SFs into previously
unaffected joints. The aim of this study was to substanti-
ate this hypothesis by investigating the role of cartilage
changes in mediating the transmigratory capacity of
RASFs in a modified Boyden chamber assay and in an in
vivo mouse model using fluorescent cell trackers. We
obtained SFs from the human tumor necrosis factor–
transgenic (hTNFtg) mouse model of RA and used inter-
leukin (IL)-1 for the induction of intra-articular (IA) car-
tilage damage because it has been shown to initiate and
mediate cartilage degradation in a mouse model of RA
without affecting synovial inflammation [14–16].
Methods
Animals
C57BL/6 wild-type (WT) mice aged 12 weeks were used
for the IA injection of cytokines and subsequent intra-
venous (IV) application of SFs. The injected SFs were
obtained from mice heterozygous for the transgene of
3′-modified human soluble tumor necrosis factor-α
(hTNFtg line Tg197, genetic background C57BL/6).
These mice were generated and kindly provided by Dr.
George Kollias and his group (Alexander Fleming Bio-
medical Sciences Research Center, Vari, Greece) [17].
For in vivo imaging and joint injections, inhalational
anesthesia (Vetland Medical Sales and Services, Louisville,
KY, USA) was performed by using 2.5% isoflurane with an
oxygen flow rate of 1.0 L/minute. For ex vivo imaging and
preparation of murine tissue, the animals were killed by
cervical dislocation. The mice were bred in the animal fa-
cility at the University Hospital Muenster under standard
conditions, and all animal procedures were approved by
the local ethics committee.
Tissues and cells
SFs were isolated from the hind paws of WT and hTNFtg
mice. The skin and surrounding tissue of the hind paw
were removed, and the synovial tissue was exposed to
enzymatic digestion as previously described [18]. Cells
were then cultured in DMEM (Sigma-Aldrich, Steinheim,
Germany) at 37 °C in a 5% CO2 atmosphere. The medium
was supplemented with 10% fetal calf serum (FCS; Bio-
chrom, Berlin, Germany), 100 U/ml penicillin, and 10 μg/
ml streptomycin (PAA Laboratories, Pasching, Austria).
Cells at passages 3–5 were used for all experiments.
Isolation of murine femoral hip cartilage was performed
as previously described [13]. In short, WT mice were
killed at an age of 4–5 weeks, hip joints were dissected,
and cartilage caps were isolated aseptically. Cartilage tis-
sue was then cultivated in high-glucose DMEM contain-
ing 10% FCS, 100 U/ml penicillin, and 10 μg/ml
streptomycin (PAA Laboratories, Pasching, Austria),
10 mM HEPES, and 50 μg/500 ml ascorbic acid for 24 h
at 37 °C in a 5% CO2 atmosphere.
In vitro transmigration assay
To study the effects of cytokines and cartilage on the
transmigration of SFs, an in vitro transmigration
assay using a modified Boyden chamber was estab-
lished (Fig. 1). For this purpose, cells from the
blood-brain barrier (brain endothelioma 5 cell line
[b.End5]), known for the formation of close tight
junctions [19], were seeded and grown to confluence
on a laminin-coated porous membrane (8-μm Trans-
well©; Sigma-Aldrich). Where indicated, the endothe-
lium was stimulated by adding 50 ng/ml recombinant
murine TNF-α (R&D Systems, Wiesbaden, Germany)
into the upper compartment to facilitate the transmi-
gration. TNF-α was removed after 4 h, and the SFs
were seeded onto the endothelial layer in the upper
compartment. Depending on the assay, the lower
compartment was filled with medium alone (10% FCS
gradient between the compartments) or with different
stimulating agents such as 10 ng/ml recombinant mur-
ine IL-1β (R&D Systems), murine cartilage hip joint ex-
plants (three cartilage hip caps per well), or 50 ng/ml
monocyte chemoattractant protein (MCP)-1 (R&D
Systems), which were added to study their chemotactic
effects on SFs. After a transmigration time of 16 h the
SFs that had successfully migrated through the b.End5
layer were trypsinized from the basal layer and counted
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using the CASY© cell counter (Roche Innovatis, Bielefeld,
Germany). In vitro transmigration assays using different
chemoattractant substrates were performed in duplicate
in at least three independent experiments.
Intra-articular cytokine injections
For the administration of cytokines, a volume of 5 μl
containing 10 ng of recombinant murine IL-1β (R&D
Systems) [15] in PBS or 5 μl of collagenase type IV
(Worthington Biochemical Corp., Lakewood, NJ, USA)
was administered by IA injection into the right knees as
previously described [20]. Briefly, the region of the knee
joint was shaved and disinfected. The joint was flexed at
90 degrees to provide access to the joint cavity at the
lower pole of the patella. The injection was performed
by puncturing the knee joint laterally from the patellar
ligament using a 32-gauge microneedle (Hamilton AG,
Bonaduz, Switzerland). The left knee joint was treated
with the same volume of PBS to serve as a control. After
the procedure, the animals were left for 48 h prior to IV
injection of SFs to incubate the cartilage with the corre-
sponding cytokine/PBS. For all IA injections, a stereo-
microscope was used (Stemi 2000-C; Carl Zeiss
Microscopy, Oberkochen, Germany).
Fluorescent dyes for cell tracking
The lipophilic cell labeling solution 1,1′-dioctadecyl-
3,3,3′,3′-tetramethylindotricarbocyanine iodide (DiR; Life
Technologies, Carlsbad, CA, USA) was used to label SFs
in vitro prior to their IV injection. The labeling was
performed following the manufacturer’s instructions. To
reduce dye transfer in vivo, cells were washed gently five
Fig. 1 Cartilage coincubation with interleukin (IL)-1 stimulates transmigration of human tumor necrosis factor–transgenic (hTNFtg) synovial
fibroblasts (SFs). a Schematic overview showing a modified Boyden chamber with a brain endothelioma 5 cell line (b.End5) layer on a laminin-coated
porous membrane. SFs were seeded onto the b.End5 layer into the upper compartment, whereas the lower compartment contained different
chemoattractant media. b Quantification of transmigrated SFs shows the significantly increased transmigration rate of hTNFtg SFs compared
with SFs derived from WT mice (WTSFs), particularly when a fetal calf serum (FCS) gradient was generated. c Quantification of transmigrated
SFs through an endothelial cell layer. hTNFtg SFs showed a significantly higher transmigratory capacity than WTSFs when migrating through
an unstimulated b.End5 endothelium. TNF-α stimulation of the b.End5 layer prior to the seeding of SFs further increased the transmigration
of both hTNFtg SFs and WTSFs, showing a significant increase for WTSFs. d Coincubation of murine cartilage explants with IL-1β in the lower
compartment significantly increased the transmigration of hTNFtg SFs. In contrast, neither cartilage nor IL-1β alone was sufficient to enhance
the transmigratory capacity of hTNFtg SFs. e Representative images of cartilage hip caps showing IL-1-induced proteoglycan loss (arrows) via
toluidine blue staining. The values represent the mean ± SEM of at least three independent experiments consisting of duplicates as x-fold of (b)
migrated WTSFs without gradient, (c) migrated WTSFs without b.End5 stimulation, or (d) migrated hTNFtg SFs without chemoattractant
medium. *p < 0.05, **p < 0.01, Student’s t test. MCP-1 Monocyte chemoattractant protein-1
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times with PBS after being labeled, followed by overnight
incubation and further washing before IV application.
In vivo fluorescence imaging
In vivo fluorescence reflectance imaging (FRI) was carried
out with the in vivo FX PRO Imaging Station (Bruker
BioSpin MRI GmbH, Ettlingen, Germany). Mice were
shaved using clippers and hair removal cream. A quan-
tity of 1 × 106 DiR-labeled hTNFtg SFs (100 μl of PBS
with 50 U/ml heparin) was injected into the tail veins
of WT mice using a 26-gauge needle. Images were
taken at different time points, namely 0 h (before IV
application) and 3 h, 6 h, 8 h, 24 h, 48 h, and 96 h after
IV application. The fluorochrome distribution and sig-
nal intensity were measured over an image acquisition
time of 30 seconds, followed by coregistration of x-ray
and white light images for the creation of overlay/fu-
sion images. The excitation light was set to 730 nm
using an appropriate bandpass filter. According to an
emission maximum of the DiR dye in the near-infrared
spectrum at 790 nm, the fluorescent signal was de-
tected using a 750-nm filter–equipped, high-sensitivity
(4 million pixels) cooled charge-coupled device camera.
After the last in vivo image was acquired, animals were
killed for the removal of internal organs and the abla-
tion of muscles and soft tissue from the skeleton,
respectively. These samples were then imaged again
separately to reduce interference and absorption by
overlaying tissue sections. For the tissue distribution of
hTNFtg SF (Fig. 2), WT mice were analyzed (n = 3),
whilst for histological quantification and for the SF
transmigration after IA cytokine injection (Figs. 3 and 4),
at least three independent experiments were performed in
each case. For the IL-1 and collagenase experiments, 16
and 9 mice were used, respectively.
Histology and histomorphometric analysis
Knee joints of the WT mice were fixed in formalin (4%)
overnight at 4 °C, decalcified in 10% ethylenediaminetet-
raacetic acid (Sigma-Aldrich) for 8 weeks and embedded
in paraffin. For the evaluation of the articular cartilage
and proteoglycan content, paraffin-embedded sections
of the joints were stained with toluidine blue. The total
amount of cartilage and the percentage of destained
cartilage as a sign of proteoglycan loss were quantified
as previously described [13].
Statistical analysis
Data are expressed as mean ± SEM. Differences between
the mean values of the groups were compared using an
unpaired, two-tailed Student’s t test. p Values below 0.05
were considered statistically significant.
Results
SFs can cross endothelial barriers
To evaluate the general ability of SFs to migrate through
endothelial junctions, an in vitro transmigration assay
was established (Fig. 1a). First, we wanted to study po-
tential differences in the transmigration rate between
hTNFtg SFs and SFs derived from WT mice (WTSFs) in-
dependent of the presence of a barrier. Although only at
very low levels, hTNFtg SFs showed a higher transmigra-
tion capacity than WTSFs (Fig. 1b) (+72% vs WTSF, p <
0.05). However, the generation of a 10% FCS gradient
led to a massive increase of transmigrated SFs of both
genotypes, particularly of hTNFtg SFs (Fig. 1b) (+77.5%
vs WTSF, p < 0.01). Next, we performed these experi-
ments using b.End5 cells as an endothelial cell layer.
Although WTSFs as well as hTNFtg SFs were able to
cross the endothelial barrier, the migratory potential of
hTNFtg SFs was significantly higher (Fig. 1c) (+104% vs
WTSFs, p < 0.05). Stimulation of the endothelial layer
with TNF-α prior to the seeding of SFs further increased
the transmigration of both cell types. Whereas hTNFtg
SFs showed only a moderate increase (+34%, p = 0.22),
the transmigration of WTSFs increased significantly
after TNF-α stimulation (+106%, p < 0.05).
To investigate potential factors that further stimulate
the transmigration of hTNFtg SFs through the endothe-
lium in vitro, we investigated the role of articular cartilage
as a chemoattractant for hTNFtg SFs. On the basis of the
established function of IL-1 in inducing structural cartil-
age damage [14], IL-1β and murine cartilage explants were
placed either alone or together into the lower compart-
ment of the chamber. Neither IL-1 nor cartilage alone was
sufficient to increase the transmigratory capacity of
hTNFtg SFs (Fig. 1d). Interestingly, the coincubation of
cartilage together with IL-1 led to a significant augmenta-
tion of hTNFtg SF transmigration through the endothelial
layer into the lower compartment (+69.8% vs control,
p < 0.01). As a control, cartilage hip caps were stained
with toluidine blue, which revealed clearly destained
areas following IL-1 incubation (Fig. 1e).
Following the evidence that preincubation of cartilage
caps with IL-1 was an essential step in inducing SF
transmigration, we also tested MCP-1, a known chemo-
attractant for SFs [21] as a transmigratory stimulus. For
this purpose, MCP-1 was placed into the lower chamber
(50 ng/ml); however, in contrast to the IL-1 experiments,
MCP-1 did not stimulate SF transmigration (−49.5% vs
control) (Fig. 1d).
hTNFtg SFs migrate into joints within hours following
their IV injection in vivo
To investigate the sites at which hTNFtg SFs leave the
bloodstream and the time course of this process, we
established an in vivo transmigration model. Therefore,
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Fig. 2 Tissue extravasation of intravenously injected 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine iodide–labeled human tumor necrosis
factor–transgenic (hTNFtg) synovial fibroblasts (SFs). a In vivo coregistration of X-rays and fluorescent signals (cyanine 7 [Cy.7] spectrum) showed an
accumulation of hTNFtg SFs in the articular and periarticular zones of the hind legs and liver over time. b Quantification of fluorescent signals revealed
an increase in intensity up to 24 h after intravenous (IV) injection of hTNFtg SFs in the regions of interest, such as the juxta-articular areas of femora
and tibiae. c–e In vivo and ex vivo fusion images of the skeleton and internal organs with quantification of the fluorescent signals. At the time of
maximal hTNFtg SF tissue extravasation 24 h after IV injection, detailed preparation and imaging of the different tissues revealed cells additionally in
the lungs, liver, spleen, and the lower part of the spinal column and forelegs. The values represent the mean ± SEM for three animals. l/s lumbosacral
Fig. 3 Interleukin (IL)-1-induced depletion of proteoglycans attracts human tumor necrosis factor–transgenic (hTNFtg) synovial fibroblasts (SFs) in vivo.
a–d Wild type mice received simultaneous intra-articular injections of (a) PBS into the left and (b) IL-1 into the right knee joints. Forty-eight hours after
injection, the cartilage of IL-1-treated knees revealed a significant loss of proteoglycans, as indicated by a higher percentage of destained cartilage
(arrows) visualized by toluidine blue staining compared with control joints, whereas the total cartilage area was not affected (c, d). In contrast, the total
amount of cartilage was equal in both groups. Scale bar = 400 μm. Mean ± SEM values are shown. ** p < 0.01, n = 4. e and f Intravenous injection of
1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine iodide–labeled hTNFtg SFs 48 h after intra-articular application of PBS/IL-1 showed significantly
increased homing into the IL-1 pretreated knee joint. The values represent mean ± SEM for 12 animals. ** p < 0.01. Cy.7 Cyanine 7
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hTNFtg SFs were stained with a lipophilic dye (DiR),
followed by IV application and subsequent detection of
the emitted fluorescent signal using an FRI chamber
[22]. In vivo imaging revealed a strong signal associated
with the large joints and adjacent bones of the hind legs
(Fig. 2a). hTNFtg SFs homed into these areas within
hours (3 h = 12.61 AU, 6 h = 17.00 AU, 8 h = 23.53 AU),
showing the highest accumulation at only 24 h (53.06 AU)
after IV application (Fig. 2b). After this time point, no
further qualitative redistribution of the hTNFtg SFs to
other tissues took place, and an apparent decay of the
fluorescent signal was observed only several days after
IV application (48 h = 53.03 AU, 96 h = 45.32 AU). For
detailed analyses, the internal organs were removed
Fig. 4 Intra-articular collagenase injection attracts human tumor necrosis factor–transgenic (hTNFtg) synovial fibroblasts (SFs) into knee joints.
a–d Wild-type mice received simultaneous intra-articular injections of (a) PBS into the left and (b) bacterial collagenase into the right knee
joints. c and d After 48 h, quantification of toluidine blue staining showed a significant proteoglycan loss (arrows) without affecting the total
cartilage area. Scale bar = 400 μm, n = 4. e and f Subsequent intravenous injection of 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine
iodide–labeled hTNFtg SFs showed increased fluorescence intensity in the collagenase-pretreated right knee joint in comparison to the control
left knee joint (n = 5). The values represent the mean ± SEM. * p < 0.05, ** p < 0.01. Cy.7 Cyanine 7
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24 h after IV injection of hTNFtg SFs, and the skeleton
was freed from muscles and connective tissue to reduce
the absorption of the signal by overlying tissue sections
(Fig. 2c). Ex vivo images showed hTNFtg SFs also in the
lungs (665.22 AU), liver (608.50 AU), spleen (358.62 AU),
spinal column (25.2 AU), and forelegs (26.3 AU) of the
animals (Fig. 2d and e).
IL-1 treatment leads to a loss of cartilage proteoglycans
and stimulates the transmigration of hTNFtg SFs into the
respective joint in vivo
On the basis of observations obtained from the in vitro
transmigration assay showing that IL-1β-mediated cartil-
age changes stimulate the transmigration of hTNFtg SFs
through an endothelial layer, we were interested in the
role of predamaged joint cartilage as a chemoattractive
stimulus for hTNFtg SF extravasation into the affected
joint. Therefore, a single IA injection of 10 ng of IL-1β
into knee joints of WT mice was performed. Histopatho-
logical analyses revealed a significant proteoglycan loss
48 h after IL-1 injection (Fig. 3a, b). The amount of
destained cartilage indicating proteoglycan depletion was
significantly higher in IL-1-treated knees compared with
control knees (PBS) (28.5% vs 4.6%, p < 0.01) (Fig. 3d),
whereas there was no significant difference in the total
amount of cartilage (146.8 mm2 vs 159.0 mm2, p = 0.08)
(Fig. 3c). No histological signs of inflammation were
detected after IA injection of either IL-1 or PBS.
To determine whether this IL-1 treatment affected the
attraction of hTNFtg SFs, we injected hTNFtg SFs intra-
venously following pretreatment of one knee joint with
IL-1 and the other with PBS. Twenty-four hours after IV
injection of hTNFtg SFs, FRI revealed a significantly
increased homing of hTNFtg SFs into IL-1-treated knee
joints compared with the PBS-treated control joints
(+11.6%, p < 0.01) (Fig. 3e, f). Furthermore, ex vivo sagittal
images of the joints showed a prominent signal in the knee
joints, the distal femur, and the proximal tibia (Fig. 3e).
Because IL-1 not only induces cartilage damage but
also constitutes an important inflammatory cytokine
with the ability to affect chondrocytes or resident SFs in
the joint in multiple ways, we also induced cartilage
damage directly by collagenase application in vivo. In line
with our IL-1 studies, we injected a single dose of 5 μl of
collagenase solution into WT murine knee joints. Similar
to the effects observed with IL-1, we found a significant
collagenase-induced destaining of the articular cartilage,
indicating proteoglycan loss (10.7% vs 3.5%, p < 0.01),
whereas no differences in the total cartilage area were de-
tected (111.72 mm2 vs 103.86 mm2). Twenty-four hours
after DiR-labeled hTNFtg SF injection, an increased signal
intensity indicating SF accumulation was detected in the
collagenase-treated knee joints compared with the control
knee joints (+10.9%, p < 0.05) (Fig. 4e, f ).
Discussion
Research conducted in recent years has revealed a
number of mechanisms, such as abundant secretion of
proinflammatory cytokines and proteases, that together
perpetuate the inflammatory response in joints of pa-
tients with RA [23]. However, the ultimate cause of RA,
as well as the changes during early stages of the disease
that lead to the dissemination of arthritis to previously
unaffected joints, remains largely unclear. In addition to
systemic autoimmunity, SFs are of interest in this con-
text because recent data derived from a SCID mouse
model demonstrated SFs’ ability to migrate long dis-
tances and to reinitiate cartilage destruction at distant
sites of subcutaneously implanted human cartilage [10].
Moreover, there is increasing evidence that in the course
of disease, not only does cartilage purely suffer damage
but early changes to the cartilage in addition to im-
munological factors and mechanisms also contribute to
fibroblast activation and thus to the switch from an
acute to a chronic, destructive disease. In fact, several
lines of evidence suggest that cartilage damage precedes
the activation of SFs at least in animal models of RA,
such as the hTNFtg mouse, and that prevention of IL-1-
induced cartilage damage significantly alters the behav-
ior of SFs in the course of this RA-like disease [13, 14].
In this study, we established an in vivo transmigra-
tion assay to visualize the tissue extravasation of
hTNFtg SFs in a time-dependent manner. We found
that circulating hTNFtg SFs migrate into joints and
adjacent bones within hours following IV injection.
Once the process of diapedesis from the bloodstream
into the joint compartments was overcome, no signifi-
cant quantitative or qualitative redistribution into
other tissues took place. This emphasizes the primary
function of SFs as resident cells in contrast to leuko-
cytes that continuously recirculate between blood and
lymphoid tissues as part of their function in immune
surveillance [24]. Nevertheless, the attraction to and
passaging of SFs at the endothelium-joint border re-
quires close interactions between hTNFtg SFs and
endothelial cells.
In vitro and in vivo studies of SFs and synovial endo-
thelium from patients with RA have shown enhanced
expression of adhesion molecules, including E-selectin,
vascular cell adhesion molecule VCAM-1, integrin α1β1
(VLA-1), intercellular adhesion molecule ICAM-1, or
junctional adhesion molecule JAM-C, resulting from the
abundant secretion of TNF-α, because a therapeutic
blockade with monoclonal antibodies effectively reduces
the expression of these molecules [25–31]. In line with
this, we found that the capability of SFs to break endo-
thelial barriers in vitro is stimulated by the presence of
TNF-α. Thus, both the endogenous expression in SFs
(hTNFtg SFs vs WTSFs) and exogenous stimulation of
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endothelial cells with this cytokine led to an enhanced
transmigratory capacity. This suggests an important role
for TNF-α in the induction of adhesion molecules that
are necessary for the transmigration of SFs through
endothelial cell layers, although specific binding partners
for this interaction are yet to be determined. However,
hTNFtg SFs were also able to leave the bloodstream at sites
of healthy, noninflamed joints of WT mice. This implies
that chemoattractants other than TNF-α are also involved
in this process. Interestingly, the joint compartments
represent the only specific site of hTNFtg SF tissue extrava-
sation because the transendothelial migration into liver,
lungs, and spleen is most likely a result of their physio-
logical function to purify and store cells from the blood.
Numerous data have shown that IL-1, another key
cytokine in RA, mediates cartilage and bone degradation
in RA [13, 16, 32]. In line with these data, we found that
IL-1-induced proteoglycan depletion in cartilage hip caps
as well as in knee joints of WT mice resulted in an in-
creased transmigration of hTNFtg SFs in vitro and in vivo.
In vitro only the coincubation of cartilage together with
IL-1, but not IL-1 or cartilage alone, was able to stimulate
the transmigration of hTNFtg SFs. The resulting notion
that structural damage induced by IL-1 significantly con-
tributes to the observed effects of IL-1 is also supported
by our experiments in which the IA injection of colla-
genase resulted in effects similar to those seen with
IL-1 treatment.
On the basis of these observations, we hypothesized
that factors released from the joint cartilage as a result
of cartilage damage are the important mediators that
attract SFs into the joint and that structural cartilage
damage increases the chemotactic effect on the trans-
migration of SFs. Although the exact nature of these
factors remains to be established, there are a number of
different possible mechanisms by which cartilage dam-
age such as that induced by our experimental proce-
dures as well as in patients with RA may lead to the
attraction of fibroblasts into joints. These include the
release of cartilage degradation products; the release of
soluble factors that are bound to the extracellular matrix
and get released as cartilage is degraded [33]; the release
of small, leucine-rich proteoglycans and other potential
damage-associated molecular pattern molecules that can
directly stimulate fibroblast-like cells via Toll-like recep-
tors; and perhaps also direct secretion of chemokines,
cytokines, growth factors, and by chondrocytes. More-
over, some of these effects may be direct, whereas others
may be indirect in that factors released from cartilage
stimulate neighboring cells in the synovial membrane,
which in turn attracts fibroblasts from the circulation
[34, 35]. Our in vitro studies using MCP-1 failed to dem-
onstrate an enhancing effect of this chemokine on SF
transmigration, but there are a variety of other
chemokines that may well play a role in this process.
Also, it needs to be emphasized that most likely it is not
only one single factor that mediates the trafficking of fi-
broblasts into predamaged joints, but that several of the
aforementioned mechanisms contribute to this process.
Conclusions
Currently, not much is known about pathological changes
that initiate and drive the progression of RA in very early
stages of the disease, despite a consensus that there are
molecular and cellular alterations, including changes in
cartilage structure, that precede the onset of synovitis in
RA [33–38]. Furthermore, why certain joints are more
likely to be affected than others remains almost com-
pletely unexplored, although there are some data derived
from microanatomical studies suggesting that mechanic-
ally exposed areas in joints are more prone to developing
synovitis [39, 40]. In the present study, we provide
evidence that structural cartilage changes that may be
present in very early phases of the disease facilitate the
homing of SFs and thus promote the spread and progres-
sion of RA. On the basis of these data, we suggest that
changes in cartilage homeostasis are not only a result but
also a potential trigger of joint destruction in RA. As a
result, early treatment of cartilage degradation may help
prevent the progression of RA and its spread to previously
unaffected joints. Although many questions about the re-
sponsible molecules and pathways remain unanswered, we
hope that our demonstration of SF homing into preda-
maged joints in this work will stimulate further research
in this area and eventually help to solve the conundrum of
disease pattern and effects on joints in RA.
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